The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

A. Voors, Adriaan; E. Angermann, Christiane; R. Teerlink, John; P. Collins, Sean; Kosiborod, Mikhail; Biegus, Jan; Pedro Ferreira, João; E. Nassif, Michael; A. Psotka, Mitchell; Tromp, Jasper; Jan Willem Borleffs, C.; Ma, Changsheng; COMINCOLET, J; Fu, Michael; Janssens, Stefan; Gábor Kiss, Róbert; J. Mentz, Robert; Sakata, Yasushi; Schirmer, Henrik; Schou, Morten; Christian Schulze, P.; Špinarová, Lenka; Volterrani, Maurizio; Krzysztof Wranicz, Jerzy; Zeymer, Uwe; Zieroth, Shelley; Brueckmann, Martina; Blatchford, Jon; Salsali, Afshin; Ponikowski, Piotr

doi:10.1038/s41591-021-01659-1

Public

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Published in Nature Medicine • Feb 28, 2022

Authors:

Adriaan A. Voors

Christiane E. Angermann

John R. Teerlink

Abstract

The sodium-glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when initiated in patients who are hospitalized for acute heart failu...

Subject

Empagliflozin

Medicine

Heart failure

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!